Donor

1. A method for protecting an acute myelogenous leukemia (AML) patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT), wherein the patient recipient expresses HLA-B genotype HLA-Bw4-I 80 , the method comprising:

(a) detecting the presence of HLA-B genotype HLA-Bw4-I 80 in a candidate donor sample obtained from a candidate donor,

(b) detecting the presence of a KIR3DL1 genotype selected from the group consisting of KIR3DL1*l/*l, KIR3DL1*l/*h, and KIR3DL1*l/KIR3DS1, in the candidate donor sample of step (a);

(i) wherein KIR3DL1*h is a KIR3DL1 allele selected from the group consisting of KIR3DL1 *001, *002, *008, *015, *020, *033, and *052,

(ii) wherein KIR3DL1*l is a KIR3DL1 allele selected from the group consisting of KIR3DL1*005, *007, and *053;

(iii) wherein the presence of HLA-Bw4-I 80 and the KIR3DL1 genotype in the candidate donor sample indicates an allele combination of HLA-Bw4-I 80 and the KIR3DL1 genotype; and

(c) administering to the patient recipient an allogeneic hematopoietic graft derived from the candidate donor expressing the allele combination of HLA-Bw4-I 80 and the KIR3DL1 genotype,

wherein HLA-Bw4-I 80 is a HLA-Bw4 genotype of Bw4-I 80 /Bw4-I 80 , Bw4-I 80 /Bw6, or Bw4-I 80 /Bw4-T 80 .

2. The method of claim 1 , wherein the allele combination of HLA-Bw4-I 80 and the KIR3DL1 genotype is detected by assaying the candidate donor sample, wherein the candidate donor sample comprises genomic nucleic acids derived from blood, blood fractions, peripheral blood cells, skin or tissue biopsies, buccal swabs or umbilical cord blood.

3. The method of claim 2 , wherein maternal and paternal KIR3DL1 alleles in the candidate donor sample are detected via sequence-specific oligonucleotide hybridization, sequencing, PCR-SSP, or any combination thereof.

4. The method of claim 1 , wherein KIR3DS1 is a KIR3DS1 allele selected from the group consisting of KIR3DS1*013, *047, *010, *011, *012, *014, *045, *046, *048, *049N, *050, *055, and *058.

5. The method of claim 1 , wherein the allogeneic hematopoietic graft is a bone marrow graft or a peripheral bone stem cell graft.

6. The method of claim 1 , wherein the hematopoietic cell transplantation is ablative, T-cell depleted, or T-cell replete.

7. The method of claim 1 , wherein the AML, patient recipient is at the early, intermediate or advanced stage of AML.

8. The method of claim 1 , wherein the patient recipient does not suffer from GVHD after the allogeneic hematopoietic cell transplantation.

9. A method for protecting an acute myelogenous leukemia (AML) patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT), wherein the patient recipient expresses HLA-B genotype HLA-Bw4-T 80 , the method comprising:

(a) detecting the presence of HLA-B genotype HLA-Bw4-T 80 in a candidate donor sample obtained from a candidate donor;

(b) detecting the presence of a KIR3DL1 genotype selected from the group consisting of KIR3DL1*h/*h, and KIR3DL1*h/KIR3DS1, in the candidate donor sample of step (a);

(i) wherein KIR3DL1*h is a KIR3DL1 allele selected from the group consisting of KIR3DL1 *001, *002, *008, *015, *020, *033, and *052;

(ii) wherein the presence of HLA-Bw4-T 80 and the KIR3DL1 genotype in the candidate donor sample indicates an allele combination of HLA-Bw4-T 80 and the KIR3DL1 genotype; and

(c) administering to the patient recipient an allogeneic hematopoietic graft derived from the candidate donor expressing the allele combination of HLA-Bw4-T 80 and the KIR3DL1 genotype ,

wherein HLA-Bw4-T 80 is a HLA-Bw4 genotype of Bw4-T 80 /Bw4-T 80 or Bw4-T 80 /Bw6; and

wherein the HLA-Bw4-T 80 genotype of the candidate donor does not comprise B*2705.

10. The method of claim 9 , wherein the allele combination of HLA-Bw4-T 80 and the KIR3DL1 genotype is detected by assaying the candidate donor sample, wherein the candidate donor sample comprises genomic nucleic acids derived from blood, blood fractions, peripheral blood cells, skin or tissue biopsies, buccal swabs or umbilical cord blood.

11. The method of claim 10 , wherein maternal and paternal KIR3DL1 alleles in the candidate donor sample are detected via sequence-specific oligonucleotide hybridization, sequencing, PCR-SSP, or any combination thereof.

12. The method of claim 9 , wherein KIR3DS1 is a KIR3DS1 allele selected from the group consisting of KIR3DS1*013, *047, *010, *011, *012, *014, *045, *046, *048, *049N, *050, *055, and *058.

13. The method of claim 9 , wherein the allogeneic hematopoietic graft is a bone marrow graft or a peripheral bone stem cell graft.

14. The method of claim 9 , wherein the hematopoietic cell transplantation is ablative, T-cell depleted, or T-cell replete.

15. The method of claim 9 , wherein the AML, patient recipient is at the early, intermediate or advanced stage of AML.

16. The method of claim 9 , wherein the patient recipient does not suffer from GVHD after the allogeneic hematopoietic cell transplantation.